醫(yī)學(xué)全在線
搜索更多精品課程:
熱 門:外科內(nèi)科學(xué)婦產(chǎn)科兒科眼科耳鼻咽喉皮膚性病學(xué)骨科學(xué)全科醫(yī)學(xué)醫(yī)學(xué)免疫學(xué)生理學(xué)病理學(xué)診斷學(xué)急診醫(yī)學(xué)傳染病學(xué)醫(yī)學(xué)影像藥 學(xué):藥理學(xué)藥物化學(xué)藥物分析藥物毒理學(xué)生物技術(shù)制藥生藥學(xué)中藥學(xué)藥用植物學(xué)方劑學(xué)衛(wèi)生毒理學(xué)檢 驗(yàn):理化檢驗(yàn) 臨床檢驗(yàn)基礎(chǔ)護(hù) 理:外科護(hù)理婦產(chǎn)科護(hù)理兒科護(hù)理 社區(qū)護(hù)理五官護(hù)理護(hù)理學(xué)內(nèi)科護(hù)理護(hù)理管理學(xué)中 醫(yī):中醫(yī)基礎(chǔ)理論中醫(yī)學(xué)針灸學(xué)刺法灸法學(xué)口 腔:口腔內(nèi)科口腔外科口腔正畸口腔修復(fù)口腔組織病理生物化學(xué):生物化學(xué)細(xì)胞生物學(xué)病原生物學(xué)醫(yī)學(xué)生物學(xué)分析化學(xué)醫(yī)用化學(xué)其 它:人體解剖學(xué)衛(wèi)生統(tǒng)計(jì)學(xué)人體寄生蟲學(xué)儀器分析健康評估流行病學(xué)臨床麻醉學(xué)社會心理學(xué)康復(fù)醫(yī)學(xué)法醫(yī)學(xué)核醫(yī)學(xué)危重病學(xué)中國醫(yī)史學(xué)
您現(xiàn)在的位置: 醫(yī)學(xué)全在線 > 精品課程 > 藥理學(xué) > 南華大學(xué) > 正文:藥理學(xué)授課教案:第二十三章 腎素-血管緊張素系統(tǒng)藥理
    

藥理學(xué)授課教案-第四篇 心血管系統(tǒng)藥理:第二十三章 腎素-血管緊張素系統(tǒng)藥理

藥理學(xué)授課教案第四篇 心血管系統(tǒng)藥理:第二十三章 腎素-血管緊張素系統(tǒng)藥理:生命科學(xué)與技術(shù)學(xué)院教 案 首 頁教研室:藥理學(xué)教師姓名:歐和生 課 程名 稱 藥理學(xué) 授課專業(yè)及班次 臨床醫(yī)學(xué)專業(yè) 授課內(nèi) 容 腎素-血管緊張素系統(tǒng)藥理 授課方式 授課時數(shù) 理論講授 2學(xué)時 目 的 要 求 1. 熟悉腎素-血管緊張素系統(tǒng)對心血管系統(tǒng)的生理機(jī)制。 2.

生命科學(xué)與技術(shù)學(xué)院

教 案 首 頁

教研室:藥理學(xué)  教師姓名:歐和生

課 程名 稱

藥理學(xué)

授課專業(yè)及班次

臨床醫(yī)學(xué)專業(yè)

授課內(nèi) 容

腎素-血管緊張素系統(tǒng)藥理

授課方式

授課時數(shù)

理論講授

2學(xué)時

1. 熟悉腎素-血管緊張素系統(tǒng)對心血管系統(tǒng)的生理機(jī)制。
2. 掌握ACEI和血管緊張素II受體I型阻滯劑的藥理作用及其機(jī)制。
3. 掌握卡托普利氯沙坦的藥理作用、臨床應(yīng)用及主要不良反應(yīng)。

點(diǎn)

點(diǎn)

重點(diǎn)

1. ACEI和血管緊張素II受體I型阻滯劑的藥理作用及其機(jī)制。

2. 托普利和氯沙坦等藥物的藥理作用、臨床應(yīng)用。

難點(diǎn)

腎素-血管緊張素系統(tǒng)對心血管系統(tǒng)調(diào)節(jié)的生理機(jī)制及藥物作用機(jī)制。

授課內(nèi)容及時間分配

1.   Renin-Aangiotensin-System (20 分鐘)

2.   Angiotensin converting enzyme inhibitors (ACEI) (45分鐘)

3.   The blockade of angiotension II receptor (20 分鐘)

4.   小結(jié)、布置思考題、安排下次課內(nèi)容 (5分鐘)

教具教材

多媒體加版書

教材:楊寶峰 主編:藥理學(xué) 人民衛(wèi)生出版社,北京,2003年

網(wǎng)

1.  周宏灝主編:藥理學(xué) 科學(xué)出版社,北京,2003年

2.  Pharmacology : 天津醫(yī)科大學(xué)藥理教研室主編,1999年

3.  H.P. Rang, M.M Dale, J.M. Ritter P.K. Moore. Pharmacology ( the fifth edition). 2003.


Part 1  Renin-Aangiotensin-System

 

Introduction

1.Element of RAS (renin, angiotensinogen,angiotensin, ACE, ATR)

Renin is an enzyme that acts on angiotensinogen to catalyze the formation of the decapeptide angiotensin I.

Angiotensin I is then cleaved by ACE to yield the octapeptide angiotensin II.

ATR: AT1R, AT2R

2.The regulation effect of RAS on blood pressure

The renin-angiotensinsystem is an important participant in both the short-and long-term regulationof arterial blood pressure.

Angiotensin II acts in several ways to increase totalperipheral resistance and thereby contributes to the short-term regulation ofarterial blood pressure. Perhaps the more important is the ability of angiotensin II to inhibit excretion of Na+ and water by thekidneys.

Angiotensin II – induced changes in renal functionplay an important role in long-term stabilization of arterial blood pressure.

Part 2  Angiotensinconverting enzyme inhibitors (ACEI)

1.Pharmacological effects

(1) Inhibit the formation of Ang II.

 (2) Maintain the activity of brandykinin (BK).

 (3) Protection of endothelium andanti-atherosclerosis

 (4) Anti-iscamiaand protection of myocardial cell

 (5) Increase the sensitivity of insulin

(6) Inhibit the pathological cardiovascular remodeling

2. Clinical uses

(1) Hypertension

(2) CHF and myocardial infarction

(3) DMEM and nephropathy

3. Untoward effects

(1) Hypotension: occurring in the first use.

(2) Cough: of 6 ~ 12%

(3) Hyperkalemia

(4) Low blood sugar

(5) Renal function trauma

(6) Affection of the development of fetus and newborn.

(7) Neuro Oedema.

(8) Malfunction of taste, tetter (thedrugs with –SH).

4.The drugs of ACEI.

. Captopril

Pharmacological Action :

 i  Directly inhibited ACE. (IC50:23 ~ 35 nmol /L), The depressor effect associated with the activitystate of RAS.

ii   The protection of heart is relatedto abolishing of ROS, such as iscamia.

Pharmacokinetics

o  Absorption : Po, F=75%. Taction :30 min. Tmax=1h.

o  Distribution: extensivelydistributed in body , Pb=30%.

o  Metabolism: oxygen in –SH.

o  Excretion: from kidney: 40-50%in parent drug and the others in metabolites.

Clinical uses

o  Hypertension: single or combination.

o  CHF

o  Cardiac infarct.

o  DMEM-nephropathy (only captopril).

Untoward effects

Apart fromthe common side effect, cough is usually complaint.

Enalapril

o  Action : the action of inhibition of ACE is 10 times stronger than captopril.

o  The absorption is not affectedby food. Po. TP=4-6h.  Tmaintain=24h,q.d.

o  Metabolism: enalaprilat(MK22)

o  Distribution extensively inbody. T1/2: 11h.

o  Excretion from kidney.

o  Uses: hypertensionbhskgw.cn/sanji/ and CHF.

o  Aside effect: cough ,hypotension, hyperkalemiaetc.

Fosinopril

o  Prodrug (poo-): fosinoprilacid is the activity chemical.

o  Tp=3-6 h

o  Pb=95%

o&bhskgw.cn/kuaiji/nbsp; T1/2=12h

o  Distribution : heart and brain(much)

o  Excretion: from liver and kidney,  no toxicityaccumulation for light malfunction of kidney.

o  No use:lactation

Lisinopril

benazepril

Part 3  The blockade of angiotension II receptor

losartan、valsartan、erbesartan、candesartan、tasosartan、eprosartan、telmisartan

1. Pharmacological effects and mechanism

 (1) Block the AT1R   vasodilatation 

     Aldostrone  Hypotension

 


(2) Block theAT1R Renin  AngII AT2RBK-NO 

Vasodilatation, regression of remodeling Hypotension.

Losartan

1.Pharmacological effects

(1)AT1R: Losartan block AT1R>AT2R (2-3萬倍).   EXP3174 >losartanin  blocking  AT1R  (10- 40 times)

(2)Vasodilate renalartery, decrease reabsorption of water and Na+in renal tube.

(3)Protect kidney:Hypertension,DM and failure of kidney.

(4)Inhibit vascular remodeling.

2. Clinical uses

 (1) Hypertension

 (2)CHF

3. Untoward effects: less than ACEI, avoid use with low efficacy diuretics.

Part 4 Howabout combination of AT1Ranta and ACEI

  1. Increase effects(cure in hypertension, CHF), decrease disadvantage of the two class drugs.

  2. Have not found anyadverse effects

Questions:

1. Describe the advantages anddisadvantages of AT1R and ACEI in therapeutics of hypertension.

2. what is thecommon side effect of Captopril?

...
關(guān)于我們 - 聯(lián)系我們 -版權(quán)申明 -誠聘英才 - 網(wǎng)站地圖 - 醫(yī)學(xué)論壇 - 醫(yī)學(xué)博客 - 網(wǎng)絡(luò)課程 - 幫助
醫(yī)學(xué)全在線 版權(quán)所有© CopyRight 2006-2046, MED126.COM, All Rights Reserved
皖I(lǐng)CP備06007007號
百度大聯(lián)盟認(rèn)證綠色會員可信網(wǎng)站 中網(wǎng)驗(yàn)證